Table 1.
Comparison of six phase III clinical trials of gemcitabine alone in patients with resected pancreatic cancer
| Trial | PRODIGE-24[1] | CONKO-001[9] | ESPAC-3[10] | JASPAC 01[13] | ESPAC-4[11] | CONKO-005[12] |
| Variable | ||||||
| No. of patients | 246 | 179 | 537 | 190 | 366 | 217 |
| Tumor grade, n (%) | ||||||
| Well differentiated | 79 (32.1) | 10 (5.6) | 66 (12.3) | NA | 30 (8.2) | 9 (4.1) |
| Moderately differentiated | 125 (50.8) | 103 (57.5) | 336 (62.6) | NA | 192 (52.5) | 128 (59) |
| Poorly differentiated/undifferentiated | 29 (11.8) | 63 (35.2) | 127 (23.6) | NA | 142 (38.8) | 74 (34.1) |
| Disease free survival - mo | ||||||
| Median | 12.8 | 13.4 | 14.3 | 11.3 | 13.1 | 11.4 |
| 95%CI | 11.7-15.2 | 11.4-15.3 | 13.5-15.6 | 9.7-13.6 | 11.6-15.3 | 9.2-13.6 |
| Overall survival - mo | ||||||
| Median | 35.0 | 22.1 | 23.6 | 25.5 | 25.5 | 26.5 |
| 95%CI | 28.7-43.9 | 18.4-25.8 | 21.4-26.4 | 22.5-29.6 | 22.7-27.9 | 22.4-30.6 |
NA: Not available; CI: Confidence interval.